Skip to Main Content

Sandhya Kharbanda


Medical Director, Pediatric BMT Program, San Francisco
Pediatric hematologist-oncologist
Bone marrow transplant specialist
Music lover

Dr. Sandhya Kharbanda is a specialist in pediatric blood disorders and stem cell transplantation, and the medical director of the pediatric blood and marrow transplant program at UCSF Benioff Children's Hospital San Francisco.

Having a special interest in stem cell transplantation for children with inherited metabolic disorders, Kharbanda aims to provide state-of-the-art care while improving both short- and long-term outcomes for these patients. She works with a multidisciplinary team to care for children who need a stem cell transplant due to leukodystrophies (genetic disorders affecting white tissues of the central nervous system), mucopolysaccharidoses, and other lysosomal storage disorders (genetic diseases in which a protein deficiency leads to toxic chemicals accumulating in cells). She is also interested in in inherited disorders of red blood cells, including thalassemia and sickle cell disease, and leads UCSF studies that evaluate new therapies for these conditions.

Kharbanda earned her medical degree from Netaji Subhash Chandra Bose Medical College, Jabalpur, in India. She completed a residency in pediatrics at SUNY Downstate Health Sciences University, part of the State University of New York system. She completed a fellowship in pediatric hematology and oncology at Children's Hospital of Pittsburgh, followed by a fellowship in pediatric bone marrow transplantation at the University of Minnesota Medical School. Prior to joining UCSF in 2017, she worked at Stanford University School of Medicine and University of Alabama at Birmingham.

  • Education

    Netaji Subhash Chandra Bose Medical College, MD, 1993

  • Residencies

    SUNY Downstate Health Sciences University, Pediatrics, 1999

  • Fellowships

    University of Pittsburgh Medical Center, Pediatric Hematology and Oncology, 2002

    University of Minnesota Medical School, Pediatric Bone Marrow Transplant, 2003

  • Academic Title

    Associate Professor

Where I see patients (1)

    Decorative Caduceus

    US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

    Calculate the proportion of recruited SCD patients for whom a suitable CBU (i.e., ≥ 6/8 human leukocyte antigen (HLA) with an appropriate cell dose) is identified.


    More about this study
    See all clinical trials

    Feeling at home

    From bedside bingo to therapy dogs, we're here to help kids smile and feel more like themselves.

    Visit Child Life services